

REMARKS

Claims 3-10, and 12-14 have been amended in order to write these claims in the appropriate U.S. claim format.

Claim 15 has been cancelled.


Claims 3-9 and 12 have been amended in order to eliminate the multiple dependencies.

Claims 16-40 have been added by the foregoing amendments. Support for claim 16 occurs, for example, in original claim 3. Support for claim 17 occurs, for example, in original claim 4. Support for claim 18 occurs, for example, in original claim 5. Support for claims 19-20 occurs, for example in original claim 6. Support for claims 21-22 occurs, for example in original claim 7. Support for claims 23-24 occurs, for example in original claim 8. Support for claims 25-32 occurs, for example in original claim 12. Support for claims 33-40 occurs, for example in original claim 14.

Claims 1-14 and 16-40 remain in the application.

Respectfully submitted,

Date: 12/16/04


Paul E. Dupont
Reg. No. 27,438

Address
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No. (610) 889-8802
Facsimile: (610) 889-8799